Not available
Quote | Myriad Genetics Inc. (NASDAQ:MYGN)
Last: | $25.47 |
---|---|
Change Percent: | 0.36% |
Open: | $25.16 |
Close: | $25.47 |
High: | $25.95 |
Low: | $24.99 |
Volume: | 1,134,706 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
News | Myriad Genetics Inc. (NASDAQ:MYGN)
2024-05-08 11:46:39 ET More on Myriad Genetics Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript Myriad Genetics, Inc. 2023 Q4 - Results - Earnings Call Presentation Myriad Genetics GAA...
2024-05-07 23:34:06 ET Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Matthew Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Co...
Message Board Posts | Myriad Genetics Inc. (NASDAQ:MYGN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $MYGN News Article - 77% of Americans have used addictive behaviors or unhealthy coping | whytestocks | investorshangout | 04/19/2023 5:55:46 PM |
whytestocks: $MYGN News Article - Illumina and Myriad Genetics expand partnership to broaden access | whytestocks | investorshangout | 03/02/2023 5:05:48 PM |
whytestocks: $MYGN News Article - Myriad Genetics Applauds New Expanded Carrier Screening Practice G | whytestocks | investorshangout | 03/01/2023 3:20:50 PM |
whytestocks: $MYGN News Article - Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare C | whytestocks | investorshangout | 01/04/2023 7:11:04 PM |
whytestocks: $MYGN News Article - Family Cancer History Still a Mystery to Many Women, Myriad Geneti | whytestocks | investorshangout | 09/28/2022 3:35:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply d...
Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal ( 22% ), Pharmacogenomics ( 21% ), and Hereditary Cancer ( 16% ). First quarter average revenue per test improved by 2% over the prior year...